NovoCure Limited (NVCR) Form 3 NovoCure / Arye Barak Ben ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Ben Arye Barak

(Last) (First) (Middle)

C/O NOVOCURE INC.,

SUITE 300

(Street)

MALVERN PA 19355

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/14/2022

3. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
General Counsel

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	4,223	D
Restricted Share Units	299(1)	D
Restricted Share Units	7,605(2)	D
Restricted Share Units	870(3)	D
Restricted Share Units	464(4)	D
Restricted Share Units	2,016(5)	D
Restricted Share Units	1,381(6)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Buy Ordinary Shares	(7)	07/30/2029	Ordinary Shares	780	83.3	D
Options to Buy Ordinary Shares	(8)	02/26/2028	Ordinary Shares	2,851	21.15	D
Options to Buy Ordinary Shares	(9)	03/02/2030	Ordinary Shares	7,990	69.37	D
Options to Buy Ordinary Shares	(10)	03/21/2029	Ordinary Shares	2,432	47.04	D
Options to Buy Ordinary Shares	(11)	03/31/2032	Ordinary Shares	13,131	87.66	D
Options to Buy Ordinary Shares	(12)	11/01/2031	Ordinary Shares	831	107.73	D
Options to Buy Ordinary Shares	(13)	02/29/2032	Ordinary Shares	3,532	80.59	D
Options to Buy Ordinary Shares	(14)	03/01/2031	Ordinary Shares	2,401	153.09	D

Explanation of Responses:

1. Represents restricted share units that are scheduled to vest on July 30, 2022, subject to the reporting person's continued employment through such dates.

2. Represents restricted share units that are scheduled to vest on April 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.

3. Represents restricted share units that are scheduled to vest on March 2, 2023 and 2024, subject to the reporting person's continued employment through such dates.

4. Represents restricted share units that are scheduled to vest on November 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.

5. Represents restricted share units that are scheduled to vest on March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.

6. Represents restricted share units that are scheduled to vest on March 3, 2023, subject to the reporting person's continued employment through such dates.

7. Options to buy 780 ordinary shares will vest in equal installments on each of July 30, 2022 and 2023, subject to the reporting person's continued employment through such dates.

8. Currently exercisable.

9. Options to buy 7,990 ordinary shares, 3,996 shares of which are currently exercisable and the remainder vest in equal installments on each of March 3, 2023 and 2024, subject to the reporting person's continued employment through such dates.

10. Options to buy 2,432 ordinary shares, 1,216 shares of which are currently exercisable and the remainder vest on March 22, 2023, subject to the reporting person's continued employment through such dates.

11. Options to buy 13,131 ordinary shares will vest in equal installments on each of April 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.

12. Options to buy 831 ordinary shares will vest in equal installments on each of November 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.

13. Options to buy 3,532 ordinary shares will vest in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.

14. Options to buy 2,401 ordinary shares, 601 shares of which are currently exercisable and the remainder vest in equal installments on each of March 2, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.

Remarks:

	By: /s/ Steven Robbins, Attorney in Fact for Barak Ben Arye	04/14/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.